Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Organ transplant treatment gap is suppressing transplant medicine market growth

Kalorama Information : 05 February, 2008  (New Product)
Kalorama Information has published a new market research report entitled ‘Organ Transplant Immunosuppressive Markets’, which highlights there is a large and growing ‘treatment gap’ between the number of patients worldwide who would benefit from an organ transplant and the number of organs available.
The report says that the gap is impacting transplant medicine markets.

In the USA, over 97,000 patients were on the United Network for Organ Sharing’s list, while just 28,000 received a transplant. Other countries show similar gaps. This gap was first evident in 1998 and has increased every year.

Immunosuppressives, drugs, which prevent the immune system from rejecting a new organ, may have become victims of their own success. Medicines such as Astella’s Prograf and Roche’s CellCept have reduced incidence of acute organ rejection and made transplantation a viable option in more cases, thus increased organ waiting lists. Kidney acute rejection rates alone decreased from 51 percent in 1996 to 13 percent eight years later as a result of these therapies. Over $5 billion worth of these drugs were sold in 2007.

“The pharmaceutical industry has created effective medications, and now the challenge is in the public policy arena,” said Bruce Carlson, publisher of Kalorama Information. “Awareness of the need for organ donation must be increased for the demand to be completely served. Volunteer efforts towards more organ donation have so far not been sufficient.”

Despite the shortage, the study indicates that the marketplace for immunosuppressives will still grow at nearly five percent for the next five years due to a small increase in transplant operations and increased survival rates of patients who will require treatment for a longer period. But the study stresses that solving the donor shortage would lead to exponential growth in transplant medicine markets.

The ‘Organ Transplant Immunosuppressive Markets’ report provides detailed statistics, market size and forecasts, trends and competitive analysis for kidney, liver, lung heart and intestine transplants.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo